Regression of Acoustic Tumor After Chemotherapy for Ovarian Cancer in a Patient With a Breast Cancer Susceptibility Gene 1 (BRCA1) Germline Mutation

Anna Takeda; Masahito Kobayashi; Kosei Hasegawa; Takamitsu Fujimaki

doi:10.7759/cureus.35917

Regression of Acoustic Tumor After Chemotherapy for Ovarian Cancer in a Patient With a Breast Cancer Susceptibility Gene 1 (BRCA1) Germline Mutation

Cureus. 2023 Mar 8;15(3):e35917. doi: 10.7759/cureus.35917. eCollection 2023 Mar.

Authors

Anna Takeda¹, Masahito Kobayashi¹, Kosei Hasegawa², Takamitsu Fujimaki¹

Affiliations

¹ Neurosurgery, Saitama Medical University Hospital, Saitama, JPN.
² Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, JPN.

Abstract

We report the case of an adult woman who developed ovarian cancer during a follow-up for vestibular schwannoma. Volume reduction of the schwannoma was observed after chemotherapy for ovarian cancer. After ovarian cancer had been diagnosed, the patient was found to have a germline mutation of breast cancer susceptibility gene 1 (BRCA1). This is the first reported case of vestibular schwannoma in a patient with a germline mutation of BRCA1 and the first documented example of chemotherapy including olaparib to have shown efficacy for schwannoma.

Keywords: acoustic tumor; brca1; brca1 germline mutation; breast cancer susceptibility gene; case report; olaparib; ovarian cancer; vestibular schwannoma.

Publication types

Case Reports